9.LudvikB, GiorginoF, JódarE.Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, ...
SCENT研究(Surpass Intracranial Aneurysm Embolization System Pivotal Trial to Treat Large or Giant Wide Neck Aneurysms)是一项多中心、前瞻性、单臂、非随机的临床试验,主要用于弹簧圈难以栓塞的或治疗失败的动脉瘤,其纳入标准为:1)瘤颈≥4mm ...
Tirzepatide is a once-weekly GIP/GLP-1 receptor agonist. In this phase 3, randomized, open-label trial, insulin-naive adults (≥18 years of age) with type 2 diabetes (T2D) uncontrolled on metformin (with or without a sulphonylurea) were randomized 1:1
Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Programdiabetes mellitus, type 2tirzepatideOBJECTIVEWe evaluated baseline characteristics of participants with early-onset type 2 diabetes (T2D) from the SURPASS program and tirzepatide's ...
Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). Diabetes Obes Metab. 2017;19(7):1024-1031. doi:10.1111/dom.12937PubMedGoogle Schol...
Trial Will Determine Who Will Pay $600 Million Settlement in Disastrous Norfolk Southern Derailment Norfolk Southern wants two other companies to help pay for the $600 million class-action settlement it agreed to over its disastrous 2023 train derailment near the Ohio-Pennsylvania ...
SURPASS-1 was a placebo-con- trolled, monotherapy trial with lower HbA1c eligibility criteria which resulted in a younger cohort (mean age 54.1 years) with a shorter duration of T2D (mean duration 4.7 years). Correspondingly, the eligibility criteria for SURPASS-4 (a high-risk ...
Background Tirzepatide, a once-weekly GIP/GLP-1 receptor agonist, reduces blood glucose and body weight in people with type 2 diabetes. The cardiovascular (CV) safety and efficacy of tirzepatide have not been definitively assessed in a cardiovascular outcomes trial. Methods Tirzepatide is being...
Figure 1. Flow of Participants in the SURPASS-6 Trial View LargeDownload See Table 3 for the details of the adverse events that led to study treatment discontinuation. aIncludes 1 participant each who did not meet baseline age criteria, had chronic or acute pancreatitis or hepatitis, receiving...
This post-hoc analysis evaluated the impact of TZP vs insulin degludec (IDeg) on post-meal glucose control. In this sub-study of the 52-week open label, parallel arm, Phase 3, SURPASS-3 trial, 243 insulin naive adults with T2D (mean age 57 years; T2D duration 8.8 years, HbA1c 8.15%...